'Celecoxib' diaporamas de présentation

Celecoxib - PowerPoint PPT Presentation

OVER-REACTIONS OF THE IMMUNE SYSTEM

OVER-REACTIONS OF THE IMMUNE SYSTEM

OVER-REACTIONS OF THE IMMUNE SYSTEM. Hypersensitivity Reactions and Allergic Diseases. OVER-REACTIONS OF THE IMMUNE SYSTEM. Hypersensitivity reactions Adaptive immune response to harmless molecules Sensitization of immune system required Mediated by antibody and effector T cells

★ ★ ★ ★ ★

2.51k views • 146 slides
????? ?????

????? ?????

????? ?????. ?????? ???. ?? ( ??? ) ?????? ??????. ????? ????? ????????. ???????. ???????. ???? ?? ??. ???? ??. ????????????. ??? Acetaminophen NSAIDs COX-2 inhibitors traditional NSAIDs, ASA Opioids Central analgesics (tramadol). ???? Local anesthetics

★ ★ ★ ★ ★

1.12k views • 60 slides
Degenerative Diseases of the CNS ??? Hsiu-Chih Liu, MD National Yang-Ming University School of Medicine

Degenerative Diseases of the CNS ??? Hsiu-Chih Liu, MD National Yang-Ming University School of Medicine

Degenerative Diseases of the CNS ??? Hsiu-Chih Liu, MD National Yang-Ming University School of Medicine Department of Neurology Taipei Veterans General Hospital . References:

★ ★ ★ ★ ★

876 views • 53 slides
Non-steroidal anti-inflammatory drugs

Non-steroidal anti-inflammatory drugs

Non-steroidal anti-inflammatory drugs. BY. PROF. AZZA EL-MEDANY. DR. OSAMA YOUSIF. OBJECTIVES. At the end of the lecture the students should : Define NSAIDs Describe the classification of this group of drugs Describe the general mechanism of actions

★ ★ ★ ★ ★

846 views • 49 slides
Cancer Prevention: Translational Research in Colon Cancer Matthew R. Young Gene Regulation Section Laboratory of Cance

Cancer Prevention: Translational Research in Colon Cancer Matthew R. Young Gene Regulation Section Laboratory of Cance

Cancer Prevention: Translational Research in Colon Cancer Matthew R. Young Gene Regulation Section Laboratory of Cancer Prevention CCR, NCI.

★ ★ ★ ★ ★

930 views • 46 slides
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA

Welcome Ask The Experts March 24-27, 2007 New Orleans, LA

Welcome Ask The Experts March 24-27, 2007 New Orleans, LA. Christopher P. Cannon, MD Senior Investigator, TIMI Study Group Cardiovascular Division Brigham and Women's Hospital Associate Professor of Medicine Harvard Medical School Boston, MA. Cardiovascular Risk with COX-IIs-

★ ★ ★ ★ ★

627 views • 37 slides
Chemoprevention of Colorectal Cancer 2011

Chemoprevention of Colorectal Cancer 2011

Chemoprevention of Colorectal Cancer 2011. First Tirana Mediterranean Cancer Congress Tirana, April 29-30, 2011. Background. Colon Cancer: Second most common cancer in developed countries Lifetime risk of 5% 1 million new cases/year 600,000 deaths/year. Background. . Early detection

★ ★ ★ ★ ★

470 views • 32 slides
The Safety of COX-2 Inhibitors

The Safety of COX-2 Inhibitors

The Safety of COX-2 Inhibitors. John J. Cush, MD Presbyterian Hospital of Dallas. RA. OA (72 %), RA (28 %). Patients. GI Outcomes Trials: Design. VIGOR (n=8076). CLASS (n=7982). Drug. Rofecoxib 50 mg QD (2x max chronic dose). Celecoxib 400 mg BID (2x max chronic dose). Comparator.

★ ★ ★ ★ ★

958 views • 29 slides
Translational Case Histories

Translational Case Histories

Translational Case Histories. Harvard Medical School Center for Biomedical Informatics i2b2 National Center for Biomedical Computing Isaac S. Kohane, MD, PhD John Glaser, PhD Susanne Churchill, PhD. First signal: 1 year after Celecoxib 8 months after Rofecoxib.

★ ★ ★ ★ ★

361 views • 25 slides
Cardiovascular Risk and NSAIDs Arthritis Advisory Committee Meeting November 29, 2006

Cardiovascular Risk and NSAIDs Arthritis Advisory Committee Meeting November 29, 2006

Cardiovascular Risk and NSAIDs Arthritis Advisory Committee Meeting November 29, 2006. Sharon Hertz, M.D. Deputy Director Division of Analgesia, Anesthesia, and Rheumatology Products Center for Drug Evaluation and Research Food and Drug Administration. Overview of Presentation.

★ ★ ★ ★ ★

570 views • 24 slides
Marie Hudson,Hugues Richard,Louise Pilote BMJ 2005;330:1370

Marie Hudson,Hugues Richard,Louise Pilote BMJ 2005;330:1370

Kaplan-Meier analysis of time to recurrent congestive heart failure or death in patients prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs. Marie Hudson,Hugues Richard,Louise Pilote BMJ 2005;330:1370.

★ ★ ★ ★ ★

191 views • 8 slides

View Celecoxib PowerPoint (PPT) presentations online in SlideServe. SlideServe has a very huge collection of Celecoxib PowerPoint presentations. You can view or download Celecoxib presentations for your school assignment or business presentation. Browse for the presentations on every topic that you want.